Healthcare / Medical DevicesShenzhen
$20.85
-0.86 (-3.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-47.9M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
N/A
•EV/EBITDA
141.9x
↑ROE
-0.2%
↓Gross Margin
22.7%
↓Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.1%
FCF CAGR
—
FCF margin
-4.9%
FCF / Net income
13.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $721.6M · net income $-2.6M · FCF $-35.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $721.6M | $721.6M | $754.1M | $842.4M | $768.5M |
| Net Income | $-2.6M | $-2.6M | $14.4M | $83.1M | $73.9M |
| EBITDA | $11.0M | $11.0M | $33.6M | $108.8M | $104.0M |
| EPS | -0.03 | -0.03 | 0.15 | 0.97 | 0.99 |
| Gross Margin | 22.7% | 22.7% | 19.9% | 25.8% | 29.2% |
| Operating Margin | 8.5% | 8.5% | 7.5% | 13.6% | 15.7% |
| Net Margin | -0.4% | -0.4% | 1.9% | 9.9% | 9.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.20 | 0.20 | 0.16 | 0.09 | 0.16 |
| Current Ratio | 2.44 | 2.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-35.2M | $-35.2M | $-47.9M | $-143.1M | $42.9M |
| Returns | |||||
| ROE | -0.2% | -0.2% | 1.1% | 6.3% | 13.3% |
| Valuation | |||||
| P/E | — | — | 117.83 | 30.50 | — |
| EV/EBITDA | 141.89 | 141.89 | 36.71 | 17.49 | — |
| P/B | 1.64 | 1.64 | 1.32 | 1.91 | — |
| Growth & Yield | |||||
| Revenue Growth | -4.3% | -4.3% | -10.5% | 9.6% | — |
| EPS Growth | -118.9% | -118.9% | -85.1% | -1.3% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.15 → -0.03
Residual
+6.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.